MA55625A - Compositions et méthodes d'administration de produits thérapeutiques - Google Patents

Compositions et méthodes d'administration de produits thérapeutiques

Info

Publication number
MA55625A
MA55625A MA055625A MA55625A MA55625A MA 55625 A MA55625 A MA 55625A MA 055625 A MA055625 A MA 055625A MA 55625 A MA55625 A MA 55625A MA 55625 A MA55625 A MA 55625A
Authority
MA
Morocco
Prior art keywords
administration
compositions
methods
therapeutic products
therapeutic
Prior art date
Application number
MA055625A
Other languages
English (en)
Inventor
Archana Belle
Stephanie Tagliatela
Original Assignee
Encoded Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Encoded Therapeutics Inc filed Critical Encoded Therapeutics Inc
Publication of MA55625A publication Critical patent/MA55625A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
MA055625A 2019-04-12 2020-04-10 Compositions et méthodes d'administration de produits thérapeutiques MA55625A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962833447P 2019-04-12 2019-04-12

Publications (1)

Publication Number Publication Date
MA55625A true MA55625A (fr) 2022-02-16

Family

ID=72750879

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055625A MA55625A (fr) 2019-04-12 2020-04-10 Compositions et méthodes d'administration de produits thérapeutiques

Country Status (17)

Country Link
US (1) US20220168449A1 (fr)
EP (1) EP3952924A4 (fr)
JP (1) JP2022526425A (fr)
KR (1) KR20220007601A (fr)
CN (1) CN114430684A (fr)
AU (1) AU2020272980A1 (fr)
BR (1) BR112021020421A2 (fr)
CA (1) CA3136646A1 (fr)
CL (1) CL2021002635A1 (fr)
CO (1) CO2021013548A2 (fr)
EA (1) EA202192801A1 (fr)
IL (1) IL287137A (fr)
MA (1) MA55625A (fr)
MX (1) MX2021012527A (fr)
SG (1) SG11202111195VA (fr)
TW (1) TW202104596A (fr)
WO (1) WO2020210633A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113966399A (zh) 2018-09-26 2022-01-21 加州理工学院 用于靶向基因疗法的腺相关病毒组合物
EP4291654A2 (fr) 2021-02-12 2023-12-20 Alnylam Pharmaceuticals, Inc. Compositions d'arni de superoxyde dismutase 1 (sod1) et procédés d'utilisation correspondants pour traiter ou prévenir des maladies neurodégénératives associées à la superoxyde dismutase 1 (sod1)
WO2025245481A1 (fr) * 2024-05-24 2025-11-27 The Regents Of The University Of California Procédés et matériel pour traiter des affections cardiaques

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040241854A1 (en) * 2002-08-05 2004-12-02 Davidson Beverly L. siRNA-mediated gene silencing
WO2007044627A2 (fr) * 2005-10-06 2007-04-19 Sloan Kettering Institute For Cancer Research Compositions et methodes d'administration d'arn interferant
BRPI0711965A2 (pt) * 2006-06-07 2012-01-24 Genzyme Corporation terapia de gene para esclerose lateral amiotrófica e outras enfermidades da medula espinal
PT3252161T (pt) * 2007-06-06 2022-02-01 Genzyme Corp Terapia genética para doenças do armazenamento lisossomal
SG10202109219SA (en) * 2009-05-02 2021-10-28 Genzyme Corp Gene therapy for neurodegenerative disorders
US10821154B2 (en) * 2013-05-01 2020-11-03 Genzyme Corporation Compositions and methods for treating spinal muscular atrophy
BR112016001592A2 (pt) * 2013-07-26 2017-11-28 Univ Iowa Res Found métodos e composições para o tratamento de doenças cerebrais
MX2017006217A (es) * 2014-11-14 2018-05-02 Voyager Therapeutics Inc Polinucleotidos moduladores.
US10123969B2 (en) * 2015-10-15 2018-11-13 Wisconsin Alumni Research Foundation Osmotic enhancement of drug/therapeutic delivery to the brain following infusion or injection into the cerebrospinal fluid
LT3411484T (lt) * 2016-02-05 2023-11-27 Emory University Viengrandžio arba sau pačiam komplementaraus adeno-asocijuoto viruso 9 injekcija į smegenų skystį
KR102674612B1 (ko) * 2016-12-01 2024-06-14 상가모 테라퓨틱스, 인코포레이티드 Tau 조절제 및 그것의 전달을 위한 방법 및 조성물
US20200040061A1 (en) * 2017-02-22 2020-02-06 Crispr Therapeutics Ag Materials and methods for treatment of early onset parkinson's disease (park1) and other synuclein, alpha (snca) gene related conditions or disorders
IL316926A (en) * 2017-05-11 2025-01-01 Univ Pennsylvania Gene therapy for neuronal ceroid lipofuscinosis
KR102636351B1 (ko) * 2017-05-19 2024-02-15 엔코디드 테라퓨틱스, 인크. 고활성 조절 요소
BR112021024055A2 (pt) * 2019-05-29 2022-02-08 Encoded Therapeutics Inc Composições e métodos para a regulação seletiva de gene

Also Published As

Publication number Publication date
CN114430684A (zh) 2022-05-03
BR112021020421A2 (pt) 2021-12-21
AU2020272980A1 (en) 2021-11-04
EP3952924A1 (fr) 2022-02-16
TW202104596A (zh) 2021-02-01
EP3952924A4 (fr) 2023-05-24
EA202192801A1 (ru) 2022-02-24
US20220168449A1 (en) 2022-06-02
CA3136646A1 (fr) 2020-10-15
WO2020210633A8 (fr) 2021-09-30
CO2021013548A2 (es) 2022-01-28
WO2020210633A1 (fr) 2020-10-15
CL2021002635A1 (es) 2022-07-15
SG11202111195VA (en) 2021-11-29
MX2021012527A (es) 2022-01-06
JP2022526425A (ja) 2022-05-24
IL287137A (en) 2021-12-01
KR20220007601A (ko) 2022-01-18

Similar Documents

Publication Publication Date Title
MA56541A (fr) Plateformes, compositions et méthodes d'administration de composés thérapeutiques
EP3924481A4 (fr) Compositions et méthodes de traitement d'hémoglobinopathies
ZA202110597B (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
EP3840730A4 (fr) Compositions pour l'administration d'agents thérapeutiques et leurs méthodes d'utilisation et leurs procédés de préparation
EP3813853A4 (fr) Compositions pour l'administration de médicaments et leurs méthodes d'utilisation
EP4034253A4 (fr) Compositions et méthodes pour accroître l'efficacité d'immunothérapies et de vaccins
EP3548000A4 (fr) Compositions pharmaceutiques d'atropine
IL285428A (en) Long lasting disinfectant cleaning compositions and methods of use thereof
EP3880688A4 (fr) Préparations et compositions d'oligosaccharides
IL279397A (en) New compounds and their pharmaceutical preparations for the treatment of diseases
EP4297784A4 (fr) Compositions et méthodes d'administration thérapeutique
EP3817747A4 (fr) Administration ciblée d'agents thérapeutiques à des adipocytes humains
EP3474857A4 (fr) Compositions et méthodes de libération d'agents thérapeutiques
IL273125A (en) Pharmaceutical formulations of cyclic oligomer of abiraterone and methods of making and taking them
GB201907558D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
EP3407925A4 (fr) Produits tissulaires f taux de support et méthodes d'utilisation
EP3713569A4 (fr) Compositions et méthodes d'administration d'une composition inhibitrice d'yap1/wwrt1 et d'une composition inhibitrice de gls1
MA55625A (fr) Compositions et méthodes d'administration de produits thérapeutiques
EP3908251A4 (fr) Compositions d'administration de produits pharmaceutiques et utilisations correspondantes
MA55291A (fr) Procédé de fabrication d'extraits bactériens stables et leur utilisation en tant que produits pharmaceutiques
EP3746058C0 (fr) Compositions et méthodes d'amélioration de la biodisponibilité de 5-hydroxytryptophane
EP3203995A4 (fr) Compositions et méthodes d'administration d'agents thérapeutiques
GB202010464D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
EP3768242A4 (fr) Méthodes et compositions pour l'administration ciblée d'agents actifs et d'agents immunomodulateurs à des ganglions lymphatiques
MA52587A (fr) Composés d'azabenzimidazole et produit pharmaceutique